6 GHP International Life Sciences Awards 2024 Australian biotechnology company, Marinova Pty Ltd, is the global leader in fucoidan science. Its unique portfolio of bioactive seaweed extracts is the result of two decades of innovative R&D. Maritech® organic fucoidan compounds represent the future of natural and sustainably sourced therapeutics. Marinova is dedicated to the production of high purity seaweed extracts for the betterment of human health. The company specialises in the research, development and manufacture of fucoidan compounds - highly bioactive polysaccharides derived from select species of brown seaweed. Sustainably sourced and clinically validated, Maritech® organic fucoidans are high purity seaweed extracts sought after by some of the world’s most trusted healthcare brands. They are included as bioactive constituents in market-leading medical devices, nutritional supplements, functional foods and beverages, skincare formulations and animal health products. Company CEO, Mr Paul Garrott, explained, “There is rapidly growing interest in marine bioproducts and for a very good reason. Bioactive compounds in this category tick all the boxes - they are natural, sustainably sourced, supported by an extensive variety of scientific evidence and have global regulatory acceptance. Maritech® organic fucoidans represent all this and more. They are ideal for any new product innovators seeking an effective, novel ingredient with a clear point of differentiation.” The granting of global regulatory approvals combined with growing investment in scientific research is now fuelling demand for high purity fucoidan. “There are now more than 3,500 peer-reviewed papers attesting to the bioactive properties fucoidans,” continued Garrott. “This extensive dossier of scientific evidence supports product applications focusing on immune support, gut and digestive health, integrative oncology and healthy ageing.” Critical to Marinova’s market leadership is the company’s proprietary ‘green chemistry’ extraction process. “Fucoidans have traditionally been precipitated from crude seaweed extracts using solvents,” explains Garrott. “This may lead to contaminants being present in the final extract. Fucoidans extracted with solvents can suffer from many shortfalls: their quality can be inconsistent, their chemical integrity may be compromised and - most importantly - their bioactivity may be affected.” Maritech® extraction technology, developed and used exclusively by Marinova, overcomes these problems. Unique aqueous processes avoid organic solvents and produce fucoidan extracts that remain unadulterated in chemical structure and free from solvent residues. The mild, aqueous process also ensures the resulting extracts comply with the most rigorous quality standards and global regulatory requirements. As the global leader in fucoidan science, Marinova is the supplier of choice to world-renowned research institutions. “Our highly characterised fucoidan fractions are well-suited to medical device applications and pharmaceutical research,” says Garrott. “Marinova also possesses the unique ability to isolate distinct fucoidan compounds with enhanced efficacy and superior compatibility with other biomaterials and therapeutic agents. Marinova is at the forefront of developing discrete fucoidans for medical research purposes. The company’s team of scientists understand the unique physicochemical properties of fucoidan extracts and how these may be tailored to influence uptake and achieve targeted therapeutic effects.” With global demand for high purity fucoidan booming, Marinova is scaling up both its research investment and production capacity. “The company has recently completed a $5M expansion of its stateof-the-art fucoidan extraction facility in Australia. The introduction of additional advanced manufacturing technologies has tripled our production capacity,” confirms Garrott. “Alongside production, Marinova continues to push the boundaries of research in the field of marine biotechnology. The company is a partner in Australia’s Marine Bioproducts Cooperative Research Centre - a dynamic consortium of industry leaders involved in a $270 million national R&D program.” Marinova continues to win favour with formulators seeking natural, efficacious ingredients supported by a sustainable supply chain. “Our sustainability credentials are closely aligned with the Sustainable Development Goals identified by United Nations,” explains Garrott. “The hand harvesting of wild seaweeds, proprietary green chemistry extraction technology, the productive reuse of by-product, and the 100% utilisation of renewable energy - the list of sustainability initiatives that support Maritech® organic fucoidans spans the entire length of our supply chain.” Maritech® fucoidans are the world’s only high purity, certified organic fucoidans with global regulatory acceptance. “After two decades of fucoidan research and production, its rewarding to see leading healthcare brands recognising the tremendous value of high purity fucoidan. Innovative marine ingredients are undoubtedly key to a sustainable future.” There is no doubt that Marinova is worthy of the International Life Sciences Awards 2024 as the Best Marine Biotechnology Company of 2024 - the company continues to pave the way for global marine innovation. Company: Marinova Pty Ltd Email: [email protected] Website: www.maritechfucoidan.com.au May24522 Best Marine Biotechnology Company 2024 – APAC
RkJQdWJsaXNoZXIy MTUyMDQwMA==